{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-045744","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2026-06-26T20:07:59+00:00","discovered_at":"2026-06-26T20:09:00.415520+00:00","generated_at":"2026-06-26T20:09:12.193075+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Context Therapeutics stockholders approve increase in authorized common shares to 300M","bullets":["Authorized common shares increased from 200M to 300M via Certificate of Amendment filed June 24, 2026.","All seven director nominees elected with >63M votes for each; no dissident candidates.","Ratification of CohnReznick LLP as independent auditor for FY2026 approved with 72.76M votes.","91.88M shares outstanding; 79.27% quorum at annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-045744","json":"https://secwatch.observer/filing/0001628280-26-045744.json","markdown":"https://secwatch.observer/filing/0001628280-26-045744.md","text":"https://secwatch.observer/filing/0001628280-26-045744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/0001628280-26-045744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026045744/cntx-20260624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:09:12.193075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}